Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Racial and socioeconomic disparities in smoldering multiple myeloma: Insights from the surveillance, epidemiology, and end Results (SEER) database.

Imran Khan, Mohammad Ebad Ur Rehman, Samra Sohail et al. Nov 03, 2025 pp. 2252-2252 10.1182/blood-2025-2252

Abstract Background: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder with the potential to progress to active mult...

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Chan Cheah, Tycel Phillips, Wojciech Jurczak et al. Nov 03, 2025 pp. 5511-5511 10.1182/blood-2025-5511

Abstract Background: Epcoritamab, a CD3×CD20 bispecific antibody, is approved for adults with relapsed/refractory large B-cell lymphoma (R/R...

Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma

Omar Elghawy, Colin Thomas, Daniel Gao et al. Nov 03, 2025 pp. 1856-1856 10.1182/blood-2025-1856

Abstract Introduction: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL), wit...

Comparative neuropsychiatric outcomes of ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia: A propensity-matched real-world cohort study

Kirti Arora, Yuvraj Kaushal, Moath Albliwi et al. Nov 03, 2025 pp. 6335-6335 10.1182/blood-2025-6335

Abstract Background: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of chronic lymphocytic...

Fulminant immune checkpoint inhibitor encephalitis associated with nivolumab: Case report and review of the literature

Jonathan Markle, Audrey Garza, Alyson Auriemma et al. Nov 03, 2025 pp. 7146-7146 10.1182/blood-2025-7146

Abstract Introduction: Immune checkpoint inhibitors (ICIs) are increasingly used in oncologic clinical practice, and have significantly impr...

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

Wenbin Qian, Panpan Chen, Hui Liu et al. Nov 03, 2025 pp. 7687-7687 10.1182/blood-2025-7687

Abstract Background: The 7×19 CAR-T cell therapy has demonstrated significant efficacy in relapsed/refractory B-cell lymphoma (R/R B-NHL), y...

Hematologic neoplasms with germline DDX41 variants: Experience from nine spanish centers.

Miguel López-Esteban, Sara Torres-Esquius, Esperanza Tuset et al. Nov 03, 2025 pp. 6744-6744 10.1182/blood-2025-6744

Abstract Introduction: Neoplasms with germline variants in DDX41 constitute the most frequent hematologic neoplasm (HN) with a germline pred...

Anemia and diabetes related mortality in older adults: Geographic and temporal trends in the US, 1999-2023

Muhammad Shaheer Bin Faheem, Sai Sushrutha Mudupula Vemula, Anam Ashfaque et al. Nov 03, 2025 pp. 6452-6452 10.1182/blood-2025-6452

Abstract Background: Diabetes is an insidiously prevailing condition across the U.S, with millions affected nationwide. It is uncontrolled a...

Increased type I interferon signaling is a hallmark of idiopathic multicentric castleman disease

Katherine Forsyth, Michael Gonzalez, Joseph Zinski et al. Nov 03, 2025 pp. 4786-4786 10.1182/blood-2025-4786

Abstract Human herpesvirus (HHV)-8-negative, idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness involving progre...

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

David Cordas Dos Santos, Hannah Thurisch, Jingke Tu et al. Nov 03, 2025 pp. 5887-5887 10.1182/blood-2025-5887

Abstract INTRODUCTION The therapeutic capacity of CAR-T cells is shaped by context-dependent factors, including their ability to traffic, ex...

Temporal control of CAR expression enables thymic generation of autoreactive T cells targeting tumor-associated antigens

Manpreet Bariana, Michael Mcguire, Andrea Tuckett et al. Nov 03, 2025 pp. 4107-4107 10.1182/blood-2025-4107

Abstract Chimeric antigen receptor (CAR) T cell therapy represents one of several cancer immunotherapies leveraging the immune system to eli...

Joint injury induces a robust proinflammatory cytokine response in hemophilia A mice: Implications for immune-mediated arthropathy

Meera Rao, Yuanhua Cai, Jocelyn Schroeder et al. Nov 03, 2025 pp. 6606-6606 10.1182/blood-2025-6606

Abstract Background: Hemophilic arthropathy, driven by repeated joint bleeds and unresolved inflammation, remains a major complication in pa...

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Arash Velayati, Alexandria Jensen, Danai Dima et al. Nov 03, 2025 pp. 6375-6375 10.1182/blood-2025-6375

Abstract Background: Real-world data suggest that safety and efficacy of ide-cel and cilta-cel mirror data from pivotal trials, yet older ad...

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Christopher Mill, Warren Fiskus, John Davis et al. Nov 03, 2025 pp. 1500-1500 10.1182/blood-2025-1500

Abstract In mutant (mt) NPM1 AML cells, treatment with Menin inhibitors (MI) disrupts the binding of Menin to MLL1, leading to reduced level...

A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation

Sophia Balderman, James Ignatz-Hoover, Claudio Brunstein et al. Nov 03, 2025 pp. 2510-2510 10.1182/blood-2025-2510

Abstract Study Rationale. 40% of AML patients and 30% of MDS patients have relapse of disease after allogeniec hematopoietic stem cell trans...

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Dimitra Karagkouni, Shivani Nanda, Patrick Foley et al. Nov 03, 2025 pp. 5801-5801 10.1182/blood-2025-5801

Abstract Introduction Understanding the tumor immune microenvironment (TIME) in multiple myeloma (MM) is critical for identifying prognostic...

Iron overload and iron chelation therapy in PNH patients on complement inhibitors: A single centre experience.

Miguel Gómez Álvarez, Fernando Ataulfo Fernandez, Estefanía Bolaños Calderón et al. Nov 03, 2025 pp. 1419-1419 10.1182/blood-2025-1419

Abstract Introduction: In untreated classic PNH, patients may develop iron defiency due to intravascular hemolysis (IVH) related haemoglobin...

Luspatercept reduces cardiac stress and improves cardiac function in a TET2-deficient mouse model with features of heart failure with preserved ejection fraction: Evidence from phase 3 commands trial and pre-clinical studies

Manuel Ugidos, Sarita Nehra, Manoj Dokania et al. Nov 03, 2025 pp. 233-233 10.1182/blood-2025-233

Abstract Introduction: Luspatercept (inhibitor of activin receptor-Smad2/3 signaling) is approved as first-line treatmen...

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

Chenwen Wang, Jin Zhou, Tao You et al. Nov 03, 2025 pp. 7256-7256 10.1182/blood-2025-7256

Abstract Background: Bispecific antibodies (bAbs) are increasingly used as bridging or maintenance therapy before chimer...

Impact of pre-transplant bone marrow cellularity and fibrosis on post-transplant outcomes in sickle cell disease

Umar Qadri, Emily Limerick, Neal Jeffries et al. Nov 03, 2025 pp. 4304-4304 10.1182/blood-2025-4304

Abstract Introduction: Sickle cell disease (SCD) is an inherited hemoglobinopathy in which erythrocytes sickle during periods of hypoxia and...

Impaired coordination between innate and adaptive immunity in hematologic and solid cancer patients following sars-cov-2 infection or vaccination

Paul Buckley, Helen Kakkassery, Theo Roumeliotis et al. Nov 03, 2025 pp. 4781-4781 10.1182/blood-2025-4781

Abstract Cancer patients, particularly with hematologic malignancies, remain a vulnerable cohort for COVID-19 disease caused by SARS-CoV-2....

Acute myeloid leukemia during the venetoclax era: Trends in survival across demographic and socioeconomic groups.

Lisa Liu, Alvaro Zevallos Barboza, Samah Nassereddine Nov 03, 2025 pp. 4602-4602 10.1182/blood-2025-4602

Abstract Background Acute myeloid leukemia (AML) has historically been associated with poor survival outcomes. In 2018,...

Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network

Matthew Whitesell, Zhaohui Su, Lisa Herms et al. Nov 03, 2025 pp. 5857-5857 10.1182/blood-2025-5857

Abstract BACKGROUND: The treatment landscape for relapsed/refractory multiple myeloma (rrMM) has continued to evolve rap...

Predicting algorithm for GRFS after allogeneic hematopoietic stem cell transplantation: A study by the SFGM-TC

Estelle Hamon, Mihaela Juganaru, Guillaume Muller et al. Nov 03, 2025 pp. 4299-4299 10.1182/blood-2025-4299

Abstract Context : Allogeneic stem cell transplantation (alloHCT) is used in majority of acute myeloid leukemia and myelodysplastic syndrome...

Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts-2

Andrius Zucenka, Lukas Kevlicius, Tautvile Smalinskaite et al. Nov 03, 2025 pp. 2415-2415 10.1182/blood-2025-2415

Abstract BACKGROUND Consolidation with allogeneic stem cell transplantation (alloSCT) after bridging therapies remains the cornerstone for r...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page